RxDoctor Payments Data

Sarpreet Basra, MD

Gastroenterology · Lake Charles, LANPI 1427224765

Payments from drug & device makers

$9,995in general payments, 2019–2025

Across 607 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$675
  • Bristol Myers Squibb$628
  • Ardelyx, Inc.$587
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$559
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$9,46795%
  • Education$5275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,995 in reported general payments places this provider in the 70th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$209,744
Medicare patients
749
Services billed
1,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa11$229,570
LinzessLinaclotide127$92,829
IbsrelaTenapanor Hcl20$48,095
XifaxanRifaximin15$40,983
VemlidyTenofovir Alafenamide28$39,842
ClenpiqSod Picosulf/Mag Ox/Citric Ac55$9,111
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates123$7,968
TrulancePlecanatide11$6,178
Pantoprazole Sodium650$5,700
Sucralfate111$4,305
Dexlansoprazole DrDexlansoprazole16$3,317
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl207$3,185
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,543
Mesalamine11$2,307
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl134$2,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,460$92,829127 claims
Ardelyx, Inc.Ibsrela$587$48,09520 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$559$47,16026 claims
GileadVemlidy$441$39,84228 claims
Ferring Pharmaceuticals Inc.Clenpiq$109$9,11155 claims
Braintree Laboratories, Inc.Sutab$90$2,54316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →